Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to vaccination in multiple sclerosis patients treated with alemtuzumab
2009-011523-31Phase 4Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alemtuzumab and haemophilus influenzae type b vaccine in multiple sclerosis (MS), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Antibody response to each vaccine. Started Apr 2009; status: terminated.
02
Drugs
alemtuzumabhaemophilus influenzae type b vaccine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2009-011523-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011523-31.